Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 15/20 | 0.74 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571276 | 0.92 | HDAC1 (0.74) | HDAC1HDAC3HDAC8HDAC2NCOR2 | |
| SCHEMBL3575706 | 0.89 | HDAC1 (0.58) | HDAC1HDAC3HDAC8HDAC2NCOR2 | |
| SCHEMBL3571974 | 0.89 | HDAC1 (0.62) | HDAC1HDAC3HDAC8HDAC2HDAC10 | |
| SCHEMBL3574458 | 0.88 | HDAC1 (0.57) | HDAC1HDAC2KDM4EMAPT | |
| SCHEMBL3575108 | 0.87 | HDAC1 (0.55) | HDAC1HDAC3HDAC8HDAC2HDAC10 | |
| SCHEMBL3562084 | 0.86 | HDAC1 (0.62) | HDAC1HDAC2 | |
| SCHEMBL3581315 | 0.86 | HDAC1 (0.55) | HDAC1HDAC2 | |
| SCHEMBL3568796 | 0.86 | HDAC1 (0.71) | HDAC1HDAC3HDAC8HDAC2NCOR2 | |
| SCHEMBL3569502 | 0.85 | HDAC1 (0.63) | HDAC1HDAC3HDAC8HDAC2HDAC10 | |
| SCHEMBL3566053 | 0.85 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | claimed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | claimed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1874295-A4 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1874295-A1 | BENZOTHIOPHENE DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006115845-A1 | BENZOTHIOPHENE DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | HDAC1 4/4885HDAC3 10/4885HDAC8 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.